RCKT (Rocket Pharmaceuticals) Tariff Resilience Score: 6/10 (As of Jul. 04, 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
30 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Tariff Resilience Score?

Rocket Pharmaceuticals RCKT +9.25% 30 Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,373 Biotechnology companies, Rocket Pharmaceuticals ranks better than 75.97% on this metric.

Rocket Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Rocket Pharmaceuticals has Biotech firm with global supply chains. While tariffs can impact raw materials, the industry often benefits from exemptions and has strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Rocket Pharmaceuticals might have Average Resilient.

Rocket Pharmaceuticals  (NAS:RCKT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Rocket Pharmaceuticals Tariff Resilience Score Related Terms

RCKT vs TENX, DMAC, AVIR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rocket Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Tariff Resilience Score falls into.


RCKT
30GF Score
Rocket Pharmaceuticals Inc RCKT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Rocket Pharmaceuticals (RCKT) has a Tariff Resilience Score of 6 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Rocket Pharmaceuticals ranks #330 out of 1373 companies in the Biotechnology industry, placing it in the top 24%.
Is Rocket Pharmaceuticals' Tariff Resilience Score too high?
Rocket Pharmaceuticals' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Rocket Pharmaceuticals' value of 6 is 50% above this industry median. Based on the distribution chart, Rocket Pharmaceuticals ranks #330 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Tariff Resilience Score compare to TENX and DMAC?
According to the Biotechnology industry distribution chart, Rocket Pharmaceuticals ranks #330 out of 1373 companies for Tariff Resilience Score. This places Rocket Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Rocket Pharmaceuticals' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rocket Pharmaceuticals's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rocket Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score

Get the complete analysis for RCKT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price